Olmesartanmedoxomil/Amlodipine Stada (Amlodipine, Olmesartan)

Olmesartanmedoxomil/Amlodipine Stada is used in cardiovascular therapy, targeting blood‑pressure regulation pathways.

• Hypertension: provides additive blood‑pressure reduction by combining an ARB with a calcium‑channel blocker.
• Isolated systolic hypertension in the elderly: improves systolic control where vascular stiffness predominates.
• Hypertension with concomitant edema risk: mitigates calcium‑channel blocker‑induced peripheral edema through vasodilatory synergy.

• The combination pairs olmesartan medoxomil, a prodrug that converts to olmesartan and selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, with amlodipine, a dihydropyridine calcium‑channel antagonist that inhibits L‑type calcium channels in vascular smooth muscle, producing arterial dilation and lowering peripheral resistance.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Peripheral edema, especially with amlodipine component
• Headache
• Flushing
• Fatigue
• Nasal congestion

Serious or Rare Side Effects

• Angio‑edema involving face, lips or airway
• Severe hypotension or syncope
• Acute kidney injury or rising serum creatinine
• Hyperkalemia
• Hepatic enzyme elevation
• Myocardial infarction in patients with unstable coronary disease

When prescribing this fixed‑dose combination, clinicians should consider several safety aspects.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess renal function: adjust use in patients with impaired kidney function.
• Check electrolytes: watch for potassium abnormalities.
• Evaluate for heart failure: use cautiously in decompensated states.
• Review concomitant medications: avoid additive hypotensive agents.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartanmedoxomil/Amlodipine Stada can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of hyperkalaemia and renal impairment.
• Potassium‑sparing diuretics or supplements: may precipitate hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise amlodipine levels, risking hypotension.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.
• Diuretics (especially thiazides): may enhance hypotensive response.
• Simvastatin or other statins metabolised by CYP3A4: increased risk of myopathy.
• Lithium: may increase serum lithium concentrations.
• Alcohol: additive central nervous system depression and blood‑pressure lowering.